舒肝解郁胶囊治疗伴抑郁症状肝硬化患者的疗效观察  

Efficacy of shuganjieyu capsule in treatment of cirrhosis patients with depressive symptoms

作　　者：计春燕[1] 刘浩[2] 谭诗云[3] 汪毅[1] 屈银宗[1] 肖卫东[2] 张彦[2] 

机构地区：[1]湖北省新华医院消化内科,湖北武汉430015 [2]武汉大学人民医院精神卫生中心,湖北武汉430060 [3]武汉大学人民医院消化内科,湖北武汉430060

出　　处：《临床消化病杂志》2015年第1期20-23,共4页Chinese Journal of Clinical Gastroenterology

摘　　要：[目的]探讨舒肝解郁胶囊对肝硬化患者伴发抑郁症状的治疗效果。[方法]51例肝硬化伴抑郁症状的患者随机分为治疗组(26例)和对照组(25例)。治疗组在常规内科综合治疗基础上同时口服舒肝解郁胶囊0.72g,bid;对照组在常规内科综合治疗基础上同时口服黛力新片1片,bid;2组疗程均为4周。于2组治疗前及治疗4周末分别采用汉密尔顿抑郁量表(HAMD-17)评定抑郁情绪分值,实验室测定肝功能。采用治疗中需处理的不良反应症状量表(TESS)评定安全性。[结果]治疗4周后,治疗组和对照组有效率分别为92%、72%(P<0.05)。治疗组HAMD评分显著下降,且治疗组的TESS评分显著低于对照组,疗效指数显著高于对照组,2组间差异有统计学意义(P<0.05)。[结论]舒肝解郁胶囊对肝硬化伴抑郁症状的患者疗效优于黛力新,且不良反应明显少于黛力新。[Objective]To explore the curative effect of shuganjieyu capsule in treatment of cirrhosis patients with depressive symptoms.[Methods]All of 51 cirrhosis patients with depressive symptoms were randomly divided into experiment group（basic medical treatment combined with shuganjieyu capsule,n=26）and control group（basic medical treatment combined with deanxit,n=25）.The patients were treatment respectively for 4weeks.Clinical effects were assessed with Hamilton Depression Scale（HAMD-17）before and after treatment.The treatment Emergent Symptoms Scale（TESS）was used to evaluate the safety.[Results]After 4weeks treatment,the efficacy of the experiment group and the control group was 92% and72%,the score of the HAMD decreased significantly in the experiment group,which was significantly different compared with control group（P〈0.05）.[Conclusions]Shuganjieyu capsule has significant effect on treatment of cirrhosis patients with depressive symptoms,which is superior to deanxit.Shuganjieyu capsule induced less side effects than deanxit.

关 键 词：肝硬化 舒肝解郁胶囊 抑郁 

分 类 号：R575.2[医药卫生—消化系统]